Median Technologies to Present at the TD Cowen 46th Annual Health Care Conference

Key Takeaways

• Median to present at TD Cowen Health Care Conference
• CEO Fredrik Brag will discuss AI SaMD milestones
• Event March 4, 2026, Boston; live webcast available
• eyonis® AI suite aims early cancer detection
• Listed on Euronext Growth; operations in US, China

Pulse Analysis

The TD Cowen 46th Annual Health Care Conference, held March 2‑4 in Boston, gathers leading investors, analysts, and innovators to dissect the evolving landscape of medical technology. By securing a speaking slot, Median Technologies places its AI‑driven diagnostic platform in front of capital‑focused audiences that shape funding trends for digital health. The conference’s fireside chats and panel discussions provide a high‑visibility forum where emerging SaaS and SaMD solutions can be benchmarked against peer innovations, amplifying market awareness for companies poised to disrupt oncology diagnostics.

Median’s flagship eyonis® suite combines deep‑learning image analysis with regulatory‑compliant Software‑as‑a‑Medical‑Device (SaMD) architecture, targeting early‑stage cancer detection across multiple tumor types. The platform’s iCRO module streamlines image management for oncology trials, reducing read‑time and variability while satisfying FDA and EMA guidelines. With operational hubs in the United States, China, and its French headquarters, Median leverages a global data pool to continuously refine algorithms, positioning itself as a critical partner for biopharma companies accelerating therapeutic development. This cross‑border footprint also supports scalable commercialization under the European SME equity savings plan.

The upcoming presentation gives investors a direct line to Median’s roadmap, including anticipated regulatory filings, partnership pipelines, and revenue milestones for 2026‑2027. As AI‑enabled diagnostics attract heightened venture and institutional capital, visibility at a premier TD Cowen event can translate into tighter analyst coverage and potentially higher valuation multiples. Moreover, the webcast ensures global stakeholders can assess how Median’s technology aligns with broader trends in precision oncology and digital health reimbursement. The exposure may accelerate licensing deals, bolster cash flow, and reinforce the company’s position ahead of its next earnings cycle.